Team

Tokyo

Hiroki Narita
Hiroki Narita

With over 20 years of experience in biotech investment, Mr. Narita founded DCI Partners. As President & CEO, he established a fund with over 10 billion JPY in capital that invests in Japan and Taiwan. He currently manages a total of 26.9 billion JPY and serves on the boards of several portfolio companies.

Shuntaro Kodama
Shuntaro Kodama

With nearly 20 years of experience in biotech investment, Mr. Kodama co-founded DCI Partners. As Senior Managing Director, he established a fund with over 10 billion JPY in capital that invests in Japan and Taiwan. He serves on the boards of several portfolio companies in both countries.

Junichi Yokota
Junichi Yokota

With over 15 years of experience in biotech investment, Mr. Yokota oversees overall management practices for biotech startups created by our fund. His responsibilities include formulating and executing business plans, as well as leading organizational development.

Kohei Katayama
Kohei Katayama

After working in R&D planning at a pharmaceutical company, Mr. Katayama joined DCI Partners in 2018. He holds a master's degree from Osaka University Graduate School of Pharmaceutical Sciences.

LingLing Liu
LingLing Liu

After working as a financial advisor in the M&A department of Daiwa Securities, Ms. Liu joined DCI Partners in 2015.

Norihide Hayakawa
Norihide Hayakawa

After working in business development in the pharmaceutical industry, Mr. Hayakawa joined DCI Partners in 2019. He holds an MBA from the National University of Singapore. He is also a pharmacist.

Shoma Tanaka
Shoma Tanaka

After working in fund and startup investment at a major Japanese financial institution, Mr. Tanaka joined DCI Partners in 2021. He holds a master's degree in medicine from Keio University, where his research focused on iPS cells and regenerative medicine, particularly in neurology.

Yuka Niimi
Yuka Niimi

After working in private equity investment at Daiwa Securities' investment department, Ms. Niimi joined DCI Partners in 2017.

Takumi Ishii
Takumi Ishii

Mr. Ishii joined DCI Partners in 2022 after working for an investment bank as an advisor on fundraising through bond issuance. He holds a master's degree in chemistry from the Graduate School of Engineering at Kyoto University.

Ryoga Kawanami
Ryoga Kawanami

Mr. Kawanami joined DCI Partners in 2024. He holds a master's degree in biological sciences from the Graduate School of Science, Osaka University, where his research focused particularly on protein functionality.

Taipei

Satoshi Motomura
Satoshi Motomura

DCI

After investing in domestic and overseas companies at our head office, Mr. Motomura has been based in Taiwan since 2008, where he has invested in Taiwanese startups, primarily in the fields of drug discovery, medical devices, and manufacturing. He also focuses on value creation, leveraging his Japanese and Taiwanese networks.

Hans Yang
Hans Yang

DCI

After a decade of legal experience at a Taiwanese manufacturer and a VC firm, Mr. Yang joined DCI Partners. Since 2010, he has overseen projects in Hong Kong and China, executing investments and exits on Chinese deals. Based in Taiwan since 2014, he manages investments in Taiwanese biotech companies and identifies opportunities in the sector.

Wei Fan Chen
Wei Fan Chen

After five years of investment experience at a major Taiwanese VC firm and a biotech-focused VC firm, Mr. Chen joined DCI Partners in 2021. He is responsible for investing in and identifying Taiwanese startups in the fields of pharmaceuticals, medical devices, and medical services. He holds a doctorate in pharmaceutical sciences.